CBD Liposomes Show Promise Against Radiation Lung Injury

Radiotherapy can damage cancer cells, but healthy tissue surrounding a tumour can also be affected. When radiation reaches the chest, the lungs may develop inflammation known as radiation pneumonitis. Finding ways to protect those lungs without weakening cancer treatment is an important research challenge.

A new study in Acta Pharmaceutica Sinica B explores an experimental approach: packaging cannabidiol, or CBD, inside tiny lipid carriers designed to resemble the lungs’ natural surfactant.¹ In laboratory cells and mice, the formulation reduced several signs of radiation injury and helped preserve respiratory function.

The findings do not establish a treatment for patients. They do, however, illustrate a promising direction for cannabinoid medicine: designing delivery systems around the tissue that needs protection, rather than relying on a compound’s biological properties alone.

Why Radiation Lung Injury Is Difficult To Address

The lungs contain millions of small air sacs called alveoli, where oxygen enters the bloodstream. Their delicate structure makes them vulnerable to radiation damage.

Part of that damage involves reactive oxygen species, chemically reactive molecules that can injure cellular structures when their production overwhelms protective systems. Radiation can also trigger inflammation and disrupt the cells responsible for maintaining healthy air sacs. Over time, injury can contribute to fibrosis, the accumulation of scar tissue that makes lungs less flexible.

Protection therefore requires more than suppressing a single inflammatory signal. Ideally, an intervention would limit the initial damage while helping preserve the systems that keep alveoli functioning.

That combination explains the researchers’ interest in CBD and pulmonary surfactant. CBD has antioxidant and anti-inflammatory activity in experimental settings. Surfactant performs a different, complementary job: reducing surface tension so the air sacs can remain open more easily.

How The CBD Delivery System Works

CBD does not readily dissolve in water, creating difficulties when researchers try to formulate it for reliable delivery. Simply mixing it into a liquid does not guarantee a stable medicine or predictable exposure.

As MyCannabis has explored in its coverage of CBD absorption and delivery innovation, formulation is an important part of cannabinoid development. The amount administered and the amount that reaches a useful biological destination can be very different.

For this study, researchers created CBD-loaded liposomes using phospholipids associated with pulmonary surfactant. Liposomes are microscopic vesicles formed from lipid membranes. They can carry compounds that would otherwise be difficult to disperse or deliver.

A Carrier Designed Around Lung Biology

The experimental formulation, abbreviated CBL, combined CBD with a surfactant-inspired lipid structure. Its purpose was to deliver CBD locally while supporting interactions with the lung’s existing surfactant system.

The researchers paid particular attention to alveolar type II cells. These cells produce surfactant and contribute to repair of the alveolar lining. Protecting them could help preserve both immediate breathing function and the capacity for recovery.

This makes the carrier more than a passive container. Its composition was selected to complement the biology of the target organ. The resulting formulation was tested against conventional CBD liposomes, empty surfactant liposomes, and dexamethasone, a corticosteroid used as an experimental comparator.

What The Experiments Found

The researchers first examined the formulation in lung epithelial cells exposed to radiation. They then studied mice receiving a single 20-gray dose of radiation to the chest.

The mice received the experimental preparations directly into the trachea, beginning one hour before irradiation. Further administrations followed on days 3, 10, and 18. This timing matters: the experiment evaluated a regimen that began before injury, rather than treatment initiated only after pneumonitis developed.

The CBD surfactant formulation produced encouraging results across several measurements. These included reduced oxidative stress and inflammatory activity, less lung swelling, and improved measures of breathing and oxygen saturation.

For three respiratory measurements, the CBL group did not differ significantly from healthy controls. That is encouraging, but statistical similarity in a small animal experiment does not prove complete recovery or establish equivalent outcomes in humans.

The study also did not show that CBL was superior to dexamethasone on every endpoint. For example, the two groups did not differ significantly in lung coefficient, a measurement relating lung weight to body weight.

Why Better Delivery Could Matter More Than More CBD

The broader insight is that cannabinoid research increasingly involves engineering the relationship between a molecule and its destination.

Increasing a dose is not always the most effective solution when a compound has poor solubility or reaches the wrong tissue. A carefully designed carrier may improve local exposure, protect the compound, or change how cells interact with it. Each possibility requires testing rather than assumption.

A recent study of oral CBD delivery formulations similarly investigated liposomes and self-microemulsifying systems. Although its route and application differ from pulmonary delivery, it reflects the same development challenge: CBD’s behaviour depends partly on its formulation.

MyCannabis has also covered hybrid nanosystems for CBD delivery, which combine materials or delivery approaches to address multiple obstacles. The lung study provides a specific example of this reasoning, pairing a cannabinoid with materials chosen for the intended organ.

The practical implication is that future CBD medicines may be highly specialised. A formulation developed for an injured lung would need its own evidence, manufacturing standards, and administration method. Results cannot automatically transfer to an oil, gummy, or product advertised simply as “nano CBD.”

The Questions That Matter Before Human Trials

The most important unresolved issue concerns cancer treatment itself. The researchers used mice without tumours. Consequently, the experiment could not determine whether the formulation might also protect tumour cells from radiation.

For an intervention intended to accompany radiotherapy, preserving healthy tissue is only part of success. Researchers must also demonstrate that tumour control is maintained. A protective effect that compromises cancer treatment would change the clinical value of the approach.

The radiation model introduces another limitation. A single high dose to the mouse chest does not reproduce every feature of human radiotherapy, which may use carefully targeted fields and multiple treatment sessions. Those differences can influence injury patterns and the window for protection.

Before clinical use, the next research priorities include:

• Testing lung protection alongside tumour response in appropriate cancer models.
• Evaluating treatment started after injury has developed.
• Establishing repeat-dose safety, practical delivery, and longer-term outcomes.

Manufacturing also matters. The authors suggest that the formulation’s phospholipid components could support larger-scale production. Nevertheless, reproducible batches, storage stability, sterility, and performance through a clinical inhalation device would still need demonstration.

Experimental Pulmonary Delivery Is Different From Vaping

Although the paper describes an inhaled strategy, the mouse experiments used direct intratracheal administration under anaesthesia. That is a controlled research procedure, and it does not establish how effectively patients would receive the formulation through a nebulizer or another inhalation device.

It also provides no evidence that vaping commercial CBD products prevents radiation injury. The ingredients, delivery conditions, and doses would be different. A formulation intended for the lungs must be evaluated specifically for that route.

For the same reason, a retail CBD buying guide would not help readers reproduce this research. The relevant development pathway is pharmaceutical testing, rather than selecting a consumer product.

A More Precise Direction For Cannabinoid Medicine

This study’s contribution is the combination of a plausible delivery strategy with measurements of tissue damage and respiratory function. The results suggest that matching CBD with lung-compatible carrier materials deserves further investigation.

Its strongest promise lies in the possibility of protecting a biological system from several connected forms of injury. Limiting oxidative stress, preserving surfactant-producing cells, and maintaining breathing function could be complementary goals.

The next milestone is demonstrating that those benefits persist in models closer to clinical care, including cancer treatment. If they do, this work could help move cannabinoid medicine toward a more precise standard: a defined formulation, delivered to a defined tissue, for a clearly tested purpose.

References:

¹ Liu, D., Sun, Y., Luo, C., Yu, X., Fang, Y., Wei, M., Xie, H., Yu, Y., & Jin, Y. (2026). Inhaled cannabidiol-loaded biomimetic pulmonary surfactant liposomes for treatment of radiation pneumonitis via highly efficient antioxidant effect and repair of injured alveolar type II cells. Acta Pharmaceutica Sinica B. Advance online publication. https://doi.org/10.1016/j.apsb.2026.10.014